AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11872893 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 11872893 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD ultrasonography monitoring
Number of subjects: 18
Study 10455841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg.kg-1
Number of subjects: 60
Study 10455841 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg
Number of subjects: 60
Study 7828316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 251
Study 7828316 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 251
Study 7828316 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 251
Study 7828316 — intervention group
Group type: COMPARATOR
Intervention: Early revascularization trial eligibility
Number of subjects: 251
Study 7828316 — intervention group
Group type: COMPARATOR
Intervention: Early revascularization
Number of subjects: 251
Study 2403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (60 mg the first day and 20 mg on successive days)
Number of subjects: 41
Study 2403867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of isosorbide dinitrate and oral diltiazem
Number of subjects: 41
Study 2403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of aspirin and vasodilators
Number of subjects: 41
Study 2403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Full therapy including heparin and beta-blockers
Number of subjects: 41
Study 552144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 400 micrograms
Number of subjects: 9
Study 552144 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 9
Study 552144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7046899 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP
Number of subjects: 131
Study 7046899 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP-A
Number of subjects: 131
Study 31595667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis knowledge assessment scale (RAKAS)
Number of subjects: 263
Study 29136160 — intervention group
Group type: EXPERIMENTAL
Intervention: 875/125mg q12h
Number of subjects: 29
Study 29136160 — intervention group
Group type: EXPERIMENTAL
Intervention: 500/125mg q8h
Number of subjects: 29
Study 29136160 — intervention group
Group type: COMPARATOR
Intervention: 500/125mg q12h
Number of subjects: 29
Study 29136160 — intervention group
Group type: COMPARATOR
Intervention: 250/125mg q8h
Number of subjects: 29
Study 26714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 657
Study 26714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 657
Study 26714411 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Acarbose and Metformin)
Number of subjects: 657
Study 24582373 — intervention group
Group type: EXPERIMENTAL
Intervention: Large electrodes (35 cm2) at equivalent current density (0.014, 0.029, 0.043 mA/cm2)
Number of subjects: 0
Study 24582373 — intervention group
Group type: COMPARATOR
Intervention: Small electrodes (16 cm2) at equivalent current density (0.014, 0.029, 0.043 mA/cm2)
Number of subjects: 0
Study 24582373 — intervention group
Group type: EXPERIMENTAL
Intervention: Large electrodes (35 cm2) at equal current intensity (0.5, 1.0, 1.5 mA)
Number of subjects: 0
Study 24582373 — intervention group
Group type: COMPARATOR
Intervention: Small electrodes (16 cm2) at equal current intensity (0.5, 1.0, 1.5 mA)
Number of subjects: 0
Study 21450574 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (CHF-E) for 12 weeks
Number of subjects: 24
Study 21450574 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CHF-S)
Number of subjects: 24
Study 21450574 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (HC)
Number of subjects: 24
Study 20457737 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated intervention with early therapeutic exercise
Number of subjects: 101
Study 20457737 — intervention group
Group type: COMPARATOR
Intervention: Standard protection, rest, ice, compression, and elevation intervention
Number of subjects: 101
Study 20457737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 17495250 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin beta-4 (Tbeta-4) administered topically
Number of subjects: 72
Study 17495250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15642038 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly L‐lactide acid‐polyglycolic acid test screws
Number of subjects: 7
Study 15642038 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium test screws
Number of subjects: 7
Study 11999595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgkg(‐1) fentanyl (Group F)
Number of subjects: 80
Study 11999595 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgkg(‐1) alfentanil (Group A)
Number of subjects: 80
Study 11999595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgkg(‐1) followed by an infusion of 0.5 pg kg min(‐1) remifentanil (Group R)
Number of subjects: 80
Study 11999595 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group P)
Number of subjects: 80
Study 9787369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (COSOPT) twice daily
Number of subjects: 253
Study 9787369 — intervention group
Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC) twice daily
Number of subjects: 253
Study 9787369 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT) three times daily
Number of subjects: 253
Study 7623395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program with nicotine patches
Number of subjects: 90
Study 7623395 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 2649221 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP (cyclophosphamide, 5‐fluorouracil, prednisone)
Number of subjects: 336
Study 2649221 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, 5‐fluorouracil, methotrexate, prednisone)
Number of subjects: 336
Study 2649221 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 336
Study 2649221 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 336
Study 381005 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)eburnamonine
Number of subjects: 106
Study 381005 — intervention group
Group type: EXPERIMENTAL
Intervention: cinnarizine
Number of subjects: 106
Study 30354794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading 1 μg/kg over 20 min followed by infusion at 0.5 μg/kg/h)
Number of subjects: 38
Study 30354794 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control group)
Number of subjects: 38
Study 28120248 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (140 Hz, 400 μs, 33 mJ)
Number of subjects: 32
Study 28120248 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser (35 Hz, 297 μs, 200 mJ)
Number of subjects: 32
Study 28120248 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 32
Study 28120248 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 32
Study 26445862 — intervention group
Group type: EXPERIMENTAL
Intervention: Onstep technique
Number of subjects: 290
Study 26445862 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 290
Study 23558107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 64
Study 23558107 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 64
Study 22046182 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin
Number of subjects: 41
Study 22046182 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 41
Study 19563365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled-tip catheter ablation
Number of subjects: 156
Study 19563365 — intervention group
Group type: COMPARATOR
Intervention: 4-mm-tip catheter ablation
Number of subjects: 156
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological abuse (limited duration: 6 months-2 years)
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological abuse (prolonged duration: >2 years)
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse without penetration
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse with penetration
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse in adulthood
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse in both adulthood and childhood
Number of subjects: 547
Study 17678462 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse in childhood only
Number of subjects: 547
Study 14975380 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl (50 microg)
Number of subjects: 32
Study 14975380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (50 microg) plus fentanyl (50 microg)
Number of subjects: 32
Study 14975380 — intervention group
Group type: COMPARATOR
Intervention: Intravenous remifentanil
Number of subjects: 32
Study 10805823 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic pacing
Number of subjects: 2568
Study 10805823 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2568
Study 9497116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-switch valve (DSV)
Number of subjects: 35
Study 9497116 — intervention group
Group type: COMPARATOR
Intervention: Conventional differential-pressure (DP) valve
Number of subjects: 35
Study 8382381 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (4 grams per 500 milligrams every eight hours)
Number of subjects: 86
Study 8382381 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 gram every eight hours)
Number of subjects: 86
Study 8382381 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 86
Study 8382381 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 86
Study 3017723 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 18
Study 3017723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30196789 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 1100
Study 30196789 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg once daily
Number of subjects: 1100
Study 28715608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 24
Study 28715608 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 24
Study 25361054 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating speed (30 minutes)
Number of subjects: 25
Study 25361054 — intervention group
Group type: COMPARATOR
Intervention: Fast eating speed (10 minutes)
Number of subjects: 25
Study 23073729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 23073729 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study 22123713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense TC with severe anemia (hemoglobin <8.0 g/dL)
Number of subjects: 622
Study 22123713 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense TC without severe anemia (hemoglobin >8.0 g/dL)
Number of subjects: 622
Study 22123713 — intervention group
Group type: COMPARATOR
Intervention: Conventional TC with severe anemia
Number of subjects: 622
Study 22123713 — intervention group
Group type: COMPARATOR
Intervention: Conventional TC without severe anemia
Number of subjects: 622
Study 19592548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal weave closure (Group A)
Number of subjects: 200
Study 19592548 — intervention group
Group type: COMPARATOR
Intervention: Routine sternal wire closure (Group B)
Number of subjects: 200
Study 17215609 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program using self-efficacy for 12 weeks
Number of subjects: 42
Study 12772814 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by local‐regional radiotherapy
Number of subjects: 506
Study 12772814 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 506
Study 10799160 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (rifampin, doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin, ciprofloxacin) for 18 weeks
Number of subjects: 50
Study 10799160 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 50
Study 9275368 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate at a dose of 6 mg/kg once a week for 8 weeks
Number of subjects: 864
Study 9275368 — intervention group
Group type: COMPARATOR
Intervention: Placebo with the same dose-schedule
Number of subjects: 864
Study 1472342 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care assistance (HCA) provided by a multidisciplinary team of caregivers; duration: 6 months; involved palliative care.
Number of subjects: 42
Study 1472342 — intervention group
Group type: COMPARATOR
Intervention: Ordinary hospital-based care (OC); duration: 6 months; included inpatient and outpatient services.
Number of subjects: 42
Study 6853785 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ointment
Number of subjects: 0
Study 6853785 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflorasone diacetate (DD) ointment
Number of subjects: 0
Study 6853785 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 30814413 — intervention group
Group type: EXPERIMENTAL
Intervention: Okara (60 g/day for 2 weeks)
Number of subjects: 60
Study 30814413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27986347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Number of subjects: 33
Study 27986347 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (CTX)
Number of subjects: 33
Study 25483421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHD) solution, wiped till day seven of life
Number of subjects: 140
Study 25483421 — intervention group
Group type: COMPARATOR
Intervention: Lukewarm water, wiped till day seven of life
Number of subjects: 140
Study 25483421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHD) solution
Number of subjects: 140
Study 24819981 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary resveratrol metabolites (mean concentration 7.08 nmol/g of creatinine)
Number of subjects: 783
Study 24819981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of total urinary resveratrol metabolites
Number of subjects: 783
Study 24819981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total urinary resveratrol metabolites quartiles
Number of subjects: 783
Study 22349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Vasoactive Inotropic Score (VIS)
Number of subjects: 76
Study 22349666 — intervention group
Group type: COMPARATOR
Intervention: Low Cardiac Output Syndrome (LCOS)
Number of subjects: 76
Study 20395261 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry (lung function variables including FEV(1), FVC, FEV(1)/FVC)
Number of subjects: 532
Study 17640545 — intervention group
Group type: EXPERIMENTAL
Intervention: New trials and therapies for treating STEMI
Number of subjects: 500000
Study 16813032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hypertonic Dead Sea saline spray
Number of subjects: 15
Study 16813032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal aqueous triamcinolone spray
Number of subjects: 15
Study 16813032 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 15
Study 11896937 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli Nissle 1917
Number of subjects: 34
Study 11896937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10535335 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation of 65 mg/day from 20 weeks of gestation
Number of subjects: 0
Study 10535335 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 10535335 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 7774471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression (NG)
Number of subjects: 480
Study 7774471 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric decompression (NG)
Number of subjects: 480
Study 1620169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (n = 352)
Number of subjects: 708
Study 1620169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 356)
Number of subjects: 708
Study 1620169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 708
Study 1620169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 708
Study 6381065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral mexiletine
Number of subjects: 240
Study 6381065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lignocaine supplemented)
Number of subjects: 240
Study 6381065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 240
Study 31386660 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN
Number of subjects: 875
Study 31386660 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN + PE
Number of subjects: 875
Study 31386660 — intervention group
Group type: EXPERIMENTAL
Intervention: PE
Number of subjects: 875
Study 31386660 — intervention group
Group type: EXPERIMENTAL
Intervention: PE + MMN
Number of subjects: 875
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum (3.16 g/L)
Number of subjects: 6481
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional milk (1.73 g/L)
Number of subjects: 6481
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature milk (0.90 g/L)
Number of subjects: 6481
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical comparison (Guangdong 1.91 g/L)
Number of subjects: 6481
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity comparison (Dai 1.80 g/L)
Number of subjects: 6481
Study 30189612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity comparison (Han 1.62 g/L)
Number of subjects: 6481
Study 26309191 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (300 μg recombinant MAGE-A3 formulated with AS15) administered concurrently with standard cisplatin/vinorelbine chemotherapy (cohort 1)
Number of subjects: 67
Study 26309191 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered after standard chemotherapy (cohort 2)
Number of subjects: 67
Study 26309191 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered without standard chemotherapy (cohort 3)
Number of subjects: 67
Study 26309191 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered after standard radiotherapy and/or chemotherapy (cohort 4)
Number of subjects: 67
Study 23872605 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (1.5g/kg on day 1 and 1.0g/kg on day 3)
Number of subjects: 56
Study 23872605 — intervention group
Group type: COMPARATOR
Intervention: Saline (isotonic saline)
Number of subjects: 56
Study 23872605 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 56
Study 23872605 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 56
Study 21817947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 50 mg/d for 5 days with tapering of doses for the next 5 days, alternatively with intravenous betamethasone 8 mg on the first 1 to 2 days if nauseated
Number of subjects: 33
Study 21817947 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic untreated)
Number of subjects: 33
Study 19401664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (2 mg/kg)
Number of subjects: 66
Study 19401664 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar infiltration of tramadol (2 mg/kg in 2 ml normal saline)
Number of subjects: 66
Study 16731324 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-ephedrine (CE)
Number of subjects: 200
Study 16731324 — intervention group
Group type: COMPARATOR
Intervention: Clonidine-saline (CS)
Number of subjects: 200
Study 16731324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam-ephedrine (DE)
Number of subjects: 200
Study 16731324 — intervention group
Group type: COMPARATOR
Intervention: Diazepam-saline (DS)
Number of subjects: 200
Study 16731324 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-ephedrine (CE) and Clonidine-saline (CS)
Number of subjects: 200
Study 16731324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (in CE and DE)
Number of subjects: 200
Study 15523663 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation containing folic acid (0.8 mg)
Number of subjects: 3056
Study 15523663 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented cohort
Number of subjects: 3056
Study 11736724 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 8 days)
Number of subjects: 15
Study 11736724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg daily for 8 days)
Number of subjects: 15
Study 9369816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution with 5% glucose (n = 48)
Number of subjects: 91
Study 9369816 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution without glucose (n = 43)
Number of subjects: 91
Study 1357701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.8 microgram/kg, once-weekly i.m. injection)
Number of subjects: 0